ESMO 2021 | Neoadjuvant therapy for melanoma

Paolo A. Ascierto, MD, National Tumor Institute, Milan, Italy, talks on the use of neoadjuvant therapy in melanoma. Both data from pre-clinical studies and clinical trials have confirmed that neoadjuvant therapy is more effective than adjuvant therapy. This is due to a higher capacity to expand tumor-resident T-cell clones. Dr Ascierto also comments on a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC), which demonstrated the of combination immunotherapy over monotherapy. This study also underlined the correlation between pathological complete response (pCR) and relapse-free survival. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.